REPL
Replimune Group Inc
NASDAQ: REPL · HEALTHCARE · BIOTECHNOLOGY
$2.38
-7.39% today
Updated 2026-04-29
Market cap
$212.21M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.44
Dividend yield
—
52W range
$2 – $13
Volume
5.4M
Replimune Group Inc (REPL) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $22.82M | $65.15M | $154.33M | $234.10M | $543.10M | $461.19M | $646.59M | $487.72M | $551.33M |
| Cash & equivalents | $20.59M | $17.58M | $25.70M | $59.50M | $182.52M | $105.95M | $146.59M | $74.46M | $111.12M |
| Current assets | $22.40M | $64.70M | $140.98M | $174.25M | $483.75M | $403.98M | $592.60M | $433.67M | $495.88M |
| Total liabilities | $34.33M | $93.22M | $16.47M | $50.38M | $44.37M | $49.96M | $91.30M | $113.21M | $135.49M |
| Current liabilities | $1.99M | $5.16M | $9.88M | $11.87M | $14.55M | $20.76M | $33.83M | $40.44M | $62.36M |
| Long-term debt | — | — | $6.56M | $9.80M | — | — | $28.65M | $44.81M | $46.38M |
| Shareholder equity | $-11.52M | $-28.07M | $137.86M | $183.72M | $498.73M | $411.23M | $555.29M | $374.51M | $415.84M |
| Retained earnings | $-9.23M | $-28.93M | $-59.77M | $-112.30M | $-193.17M | $-311.20M | $-485.49M | $-701.28M | $-948.58M |
| Accounts receivable | $1.41M | $2.39M | $2.47M | $2.96M | $2.95M | $3.06M | $2.94M | $4.92M | $3.73M |
| Inventory | — | — | — | $-2.96M | $-2.95M | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — | — | — |